Riluzole

• 

  Subject Areas on Research

  • A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. 
  • Amyotrophic lateral sclerosis: current practice and future treatments. 
  • Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. 
  • Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. 
  • Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. 
  • Efficacy of Glutamate Modulators in Tic Suppression: A Double-Blind, Randomized Control Trial of D-serine and Riluzole in Tourette Syndrome. 
  • Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold. 
  • Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent. 
  • Pharmacology of riluzole in acute spinal cord injury. 
  • Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial. 
  • Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. 
  • The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1.